Shattuck Labs Announces Participation in Upcoming December Conferences
Shattuck Labs (NASDAQ: STTK), a biotechnology company developing novel therapeutics targeting TNF superfamily receptors for cancer and chronic immune-related diseases treatment, announced its participation in two upcoming investor conferences. The company's CEO, Dr. Taylor Schreiber, will present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 12:30 p.m. ET, and participate in a fireside chat at the Evercore 7th Annual HealthCONx Conference on December 4, 2024, at 8:45 a.m. ET. Live webcasts will be available on the company's website with replays archived for up to 90 days.
Shattuck Labs (NASDAQ: STTK), un'azienda biotecnologica che sviluppa nuovi farmaci mirati ai recettori della superfamiglia TNF per il trattamento del cancro e delle malattie croniche legate al sistema immunitario, ha annunciato la sua partecipazione a due prossime conferenze per investitori. Il CEO dell'azienda, Dr. Taylor Schreiber, presenterà alla Piper Sandler 36th Annual Healthcare Conference il 3 dicembre 2024, alle 12:30 p.m. ET, e parteciperà a una chiacchierata informale alla Evercore 7th Annual HealthCONx Conference il 4 dicembre 2024, alle 8:45 a.m. ET. Saranno disponibili webcast dal vivo sul sito web dell'azienda con le registrazioni archiviate per un massimo di 90 giorni.
Shattuck Labs (NASDAQ: STTK), una empresa biotecnológica que desarrolla nuevas terapias dirigidas a los receptores de la superfamilia TNF para el tratamiento del cáncer y enfermedades crónicas relacionadas con el sistema inmune, anunció su participación en dos próximas conferencias para inversores. El CEO de la empresa, Dr. Taylor Schreiber, presentará en la Piper Sandler 36th Annual Healthcare Conference el 3 de diciembre de 2024, a las 12:30 p.m. ET, y participará en una charla informal en la Evercore 7th Annual HealthCONx Conference el 4 de diciembre de 2024, a las 8:45 a.m. ET. Habrá transmisiones en vivo disponibles en el sitio web de la empresa y grabaciones archivadas por hasta 90 días.
Shattuck Labs (NASDAQ: STTK)는 암 및 만성 면역 관련 질병 치료를 위한 TNF 초가족 수용체를 목표로 하는 혁신적인 치료제를 개발하는 생명공학 회사로, 두 개의 다가오는 투자자 회의에 참여한다고 발표했습니다. 회사의 CEO인 Dr. Taylor Schreiber는 2024년 12월 3일 오후 12시 30분 ET에 Piper Sandler 제36회 연례 헬스케어 회의에서 발표하고, 2024년 12월 4일 오전 8시 45분 ET에 Evercore 제7회 HealthCONx 회의에서 대화에 참여할 예정입니다. 회사 웹사이트에서 라이브 웹캐스트가 제공되며, 90일 동안 재생 기록 보관이 가능합니다.
Shattuck Labs (NASDAQ: STTK), une entreprise de biotechnologie développant de nouveaux traitements ciblant les récepteurs de la superfamille TNF pour le traitement du cancer et des maladies chroniques liées au système immunitaire, a annoncé sa participation à deux conférences pour investisseurs à venir. Le PDG de l'entreprise, Dr. Taylor Schreiber, présentera lors de la Piper Sandler 36th Annual Healthcare Conference le 3 décembre 2024 à 12h30 ET et participera à une discussion informelle lors de la Evercore 7th Annual HealthCONx Conference le 4 décembre 2024 à 8h45 ET. Des webcasts en direct seront disponibles sur le site de l'entreprise, avec des rediffusions archivées pendant 90 jours.
Shattuck Labs (NASDAQ: STTK), ein biopharmazeutisches Unternehmen, das neuartige Therapeutika zur Bekämpfung von Krebs und chronischen immunologischen Erkrankungen entwickelt, gab seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt. Der CEO des Unternehmens, Dr. Taylor Schreiber, wird am 3. Dezember 2024 um 12:30 Uhr ET auf der Piper Sandler 36th Annual Healthcare Conference präsentieren und am 4. Dezember 2024 um 8:45 Uhr ET an einem Gespräch bei der Evercore 7th Annual HealthCONx Conference teilnehmen. Live-Webcasts werden über die Unternehmenswebsite verfügbar sein und Zuschauermitschnitte werden bis zu 90 Tage lang archiviert.
- None.
- None.
AUSTIN, TX and DURHAM, NC, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with cancer and chronic immune-related diseases, today announced that company management will participate in two investor conferences in December 2024.
Presentation Details
Conference: Piper Sandler 36th Annual Healthcare Conference
Format: Corporate Presentation
Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: December 3, 2024
Time: 12:30 p.m. ET
Conference: Evercore 7th Annual HealthCONx Conference
Format: Fireside chat with covering analyst, Jonathan Miller, Ph.D.
Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: December 4, 2024
Time: 8:45 a.m. ET
A live webcast of the presentation and fireside chat will be available on the Investors section of the Company’s website. A replay of the webcast will be archived for up to 90 days following the presentation date.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (Nasdaq: STTK) is a biotechnology company specializing in the development of potential treatments for autoimmune/inflammatory diseases and cancer. The Company is developing a potentially first-in-class antibody for the treatment of IBD and other inflammatory autoimmune diseases. Shattuck's expertise in protein engineering and the development of novel TNF receptor agonist and antagonist therapeutics come together in its lead program, SL-325, a first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated TL1A/DR3 pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.
Investor & Media Contact:
Conor Richardson
Vice President of Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
FAQ
When is Shattuck Labs (STTK) presenting at the Piper Sandler Healthcare Conference in 2024?
What conferences will Shattuck Labs (STTK) attend in December 2024?
How long will Shattuck Labs (STTK) conference webcasts be available for replay?
